InChI | 1S/C17H23N7O5/c1-23-13(25)6-10(22-17(23)29)15(27)21-11(5-9-7-19-8-20-9)16(28)24-4-2-3-12(24)14(18)26/h7-8,10-12H,2-6H2,1H3,(H2,18,26)(H,19,20)(H,21,27)(H,22,29)/t10-,11-,12-/m0/s1 |
Reference | 1: Dougherty JP, Wolff BS, Cullen MJ, Saligan LN, Gershengorn MC. Taltirelin
alleviates fatigue-like behavior in mouse models of cancer-related fatigue.
Pharmacol Res. 2017 Oct;124:1-8. doi: 10.1016/j.phrs.2017.07.012. Epub 2017 Jul
15. PubMed PMID: 28720519; PubMed Central PMCID: PMC5587390.
<br>
2: Thirunarayanan N, Nir EA, Raaka BM, Gershengorn MC. Thyrotropin-releasing
hormone receptor type 1 (TRH-R1), not TRH-R2, primarily mediates taltirelin
actions in the CNS of mice. Neuropsychopharmacology. 2013 May;38(6):950-6. doi:
10.1038/npp.2012.256. Epub 2012 Dec 11. PubMed PMID: 23303050; PubMed Central
PMCID: PMC3629383.
<br>
3: Thirunarayanan N, Raaka BM, Gershengorn MC. Taltirelin is a superagonist at
the human thyrotropin-releasing hormone receptor. Front Endocrinol (Lausanne).
2012 Oct 9;3:120. doi: 10.3389/fendo.2012.00120. eCollection 2012. PubMed PMID:
23087672; PubMed Central PMCID: PMC3466466.
<br>
4: Eto K, Kim SK, Nabekura J, Ishibashi H. Taltirelin, a thyrotropin-releasing
hormone analog, alleviates mechanical allodynia through activation of descending
monoaminergic neurons in persistent inflammatory pain. Brain Res. 2011 Sep
26;1414:50-7. doi: 10.1016/j.brainres.2011.07.065. Epub 2011 Aug 6. PubMed PMID:
21872219.
<br>
5: Nakamura T, Honda M, Kimura S, Tanabe M, Oda S, Ono H. Taltirelin improves
motor ataxia independently of monoamine levels in rolling mouse nagoya, a model
of spinocerebellar atrophy. Biol Pharm Bull. 2005 Dec;28(12):2244-7. PubMed PMID:
16327158.
<br>
6: Fukuchi I, Asahi T, Kawashima K, Kawashima Y, Yamamura M, Matsuoka Y,
Kinoshita K. Effects of taltirelin hydrate (TA-0910), a novel
thyrotropin-releasing hormone analog, on in vivo dopamine release and turnover in
rat brain. Arzneimittelforschung. 1998 Apr;48(4):353-9. PubMed PMID: 9608876.
|